Please login to the form below

Not currently logged in

renal disorders

This page shows the latest renal disorders news and features for those working in and with pharma, biotech and healthcare.

Merck & Co signs deal with Amathus for neurodegenerative diseases

Merck & Co signs deal with Amathus for neurodegenerative diseases

In addition, Merck &Co will also retain the option to acquire Amathus and its pipeline containing mitochondrial targeted candidates for the treatment of neurodegenerative disorders and renal diseases.

Latest news

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...